| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/27/2002 | WO2002049647A2 Novel therapeutic use of a thienylcyclohexylamine derivative |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049644A1 Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders |
| 06/27/2002 | WO2002049643A1 Treatment of depression |
| 06/27/2002 | WO2002049642A2 Use of 5-hydroxy and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acids and their esters as agents useful for healing skin lesions and stimulants of angiogenesis |
| 06/27/2002 | WO2002049641A2 Anti-endoparasitic amidoacetonitrils |
| 06/27/2002 | WO2002049640A1 Triglyceride depressant composition |
| 06/27/2002 | WO2002049639A1 Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis |
| 06/27/2002 | WO2002049638A1 Medicinal granular preparation containing branched amino acids |
| 06/27/2002 | WO2002049637A1 A novel soft-gelatin capsule comprising s-adenosylmethionine and a method for producing the same |
| 06/27/2002 | WO2002049636A1 An antidiabetic composition of amino acids |
| 06/27/2002 | WO2002049635A2 Use of 5-aminolevulinic acid for the prophylaxis of restenosis |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049633A2 Use of amidoamines to treat or prevent acanthamoeba and fungal infections |
| 06/27/2002 | WO2002049632A1 Inhibitors against the production and release of inflammatory cytokines |
| 06/27/2002 | WO2002049631A1 Propofol formulation with enhanced microbial inhibition |
| 06/27/2002 | WO2002049630A2 Method for preventing or treating pain by administering an endothelin antagonist |
| 06/27/2002 | WO2002049629A2 Methods for reducing chronic stress in mammals |
| 06/27/2002 | WO2002049628A2 Methods of treating anxiety disorders |
| 06/27/2002 | WO2002049627A2 Antifungal compositions containing an antibiotic and one or more amidoamines |
| 06/27/2002 | WO2002049626A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002049624A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists |
| 06/27/2002 | WO2002049622A2 Transdermal system containing a novel high potency progestagen |
| 06/27/2002 | WO2002049620A2 Induced phase transition method for the production of microparticles containing hydrophobic active agents |
| 06/27/2002 | WO2002049619A2 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 06/27/2002 | WO2002049618A1 Amoxycillin pellets |
| 06/27/2002 | WO2002049617A2 Self forming, thermodynamically stable liposomes and their applications |
| 06/27/2002 | WO2002049616A1 Pharmaceutical aerosol formulation |
| 06/27/2002 | WO2002049613A2 Method for enhancing integrity of epithelium using retinoic acid |
| 06/27/2002 | WO2002049611A2 Ophthalmic lubricating solution adapted for use in lasik surgery |
| 06/27/2002 | WO2002049610A2 Ophthalmic irrigating solution adapted for use in lasik surgery |
| 06/27/2002 | WO2002049606A2 Transdermal systems (tds) that contain inhibitors of phosphodiesterase iv |
| 06/27/2002 | WO2002049603A1 Compositions for prevention and alleviation of skin wrinkles |
| 06/27/2002 | WO2002049599A2 Filtering composition containing a 1,3,5-triazine derivative, a dibenzoylmethane derivative, and a 4,4-diarylbutadiene compound |
| 06/27/2002 | WO2002049593A2 Use of dna repair enzymes as mmp-1 inhibitors |
| 06/27/2002 | WO2002049590A2 Antiperspirant products |
| 06/27/2002 | WO2002049580A1 Compositions and methods for treating hyperpigmentation |
| 06/27/2002 | WO2002049577A2 Analogues of thiocoraline and be-22179 |
| 06/27/2002 | WO2002049576A2 Fab i and inhibition of apicomplexan parasites |
| 06/27/2002 | WO2002049575A2 Method and composition for the treatment of diabetic neuropathy |
| 06/27/2002 | WO2002049557A1 Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate |
| 06/27/2002 | WO2002049501A2 Local regional chemotherapy and radiotherapy using in situ hydrogel |
| 06/27/2002 | WO2002049457A1 The use of a non-absorbable, non-digestible lipid for the treatment of hyperbilirubinemia |
| 06/27/2002 | WO2002049413A2 Thrombopoietin mimetics |
| 06/27/2002 | WO2002034232A3 Use of carotenoids for treating ageing symptoms |
| 06/27/2002 | WO2002034231A3 Use of the association of at least an plant extract of genus rosmarinus and of at least a carotenoid |
| 06/27/2002 | WO2002030879A3 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| 06/27/2002 | WO2002030390A3 Method for producing powdery formulations |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002028814A3 Nmda receptor channel blocker with neuroprotective activity |
| 06/27/2002 | WO2002026222A8 Method of achieving overnight laxation and control of bowel function |
| 06/27/2002 | WO2002024652B1 Compounds and methods for diagnosing and treating amyloid-related conditions |
| 06/27/2002 | WO2002024613A3 Resorcinol derivatives |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002022592A3 Substituted urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020501A3 Polyarylcarboxamides useful as lipid lowering agents |
| 06/27/2002 | WO2002015881A3 Use of a porous carrier |
| 06/27/2002 | WO2002009704A3 Pharmaceutical composition for transdermal delivery of befloxatone |
| 06/27/2002 | WO2002009648A3 Antimicrobial biaryl compounds |
| 06/27/2002 | WO2002008231A3 Biologically active macrolides, compositions, and uses thereof |
| 06/27/2002 | WO2002007516A3 Uses for nad synthetase inhibitors |
| 06/27/2002 | WO2002006821A3 Antimicrobial agent |
| 06/27/2002 | WO2002005844A3 Protein complex serving as a vehicle for orally administerable medicaments |
| 06/27/2002 | WO2002003992A3 Use of substituted indole compounds for treating prosthesis-related bone degeneration |
| 06/27/2002 | WO2002002182A3 Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system |
| 06/27/2002 | WO2002002069A3 Cosmetic compositions containing substituted amine derivatives |
| 06/27/2002 | WO2002000616A3 Novel cephalosporin compounds and process for preparing the same |
| 06/27/2002 | WO2002000196A3 Wet milling process |
| 06/27/2002 | WO2001097838A3 Adjuvants and processes to induce a specific type of immune response |
| 06/27/2002 | WO2001097788A3 Method of administering bisphosphonates |
| 06/27/2002 | WO2001096298A3 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 06/27/2002 | WO2001096286A3 Urokinase inhibitors |
| 06/27/2002 | WO2001093878A8 Bismuth compounds for the treatment and prevention of mucositis |
| 06/27/2002 | WO2001093853A8 Management of snoring by oral administration of dimethyl sulfone |
| 06/27/2002 | WO2001092267A3 Dihydropyridine compounds for the inhibition of calcium-influx |
| 06/27/2002 | WO2001087938A3 Polynucleotide sequence encoding a putative cell adhesion molecule |
| 06/27/2002 | WO2001087280A3 Means for treating attacks of auto-immune diseases |
| 06/27/2002 | WO2001081182A3 Improved method and apparatus for generating an aerosol |
| 06/27/2002 | WO2001080857A9 Zolpidem hemitartrate |
| 06/27/2002 | WO2001078781A8 Methods for prevention and treatment of gastrointestinal disorders |
| 06/27/2002 | WO2001077375A3 Diagnosis of diseases associated with gene regulation |
| 06/27/2002 | WO2001076600A3 Inhibition of cytokine generation |
| 06/27/2002 | WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 06/27/2002 | WO2001076569A3 An improved pt(iv) antitumor agent |
| 06/27/2002 | WO2001074330A3 Method for treating dry eye |
| 06/27/2002 | WO2001072293A3 Antiprogestins with partial agonist activity |
| 06/27/2002 | WO2001070978A3 Polypeptides and nucleic acids encoding same |
| 06/27/2002 | WO2001054680A3 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/27/2002 | WO2001053257A3 Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
| 06/27/2002 | WO2001051051A3 Agents, such as nicotinamide or cadpr for the treatment of skin disorders |
| 06/27/2002 | WO2001040182A3 Solid pharmaceutical preparation |
| 06/27/2002 | WO2001030393A8 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 06/27/2002 | WO2001026605A3 Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor |
| 06/27/2002 | WO2001022957A3 Use of gangliosides and other substances for modulating sphingolipid-cholesterol microdomains |
| 06/27/2002 | WO2001018171A3 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| 06/27/2002 | WO2001014536A3 Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence |
| 06/27/2002 | WO2000071561A9 Cd4-independent hiv envelope proteins as vaccines and therapeutics |